BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry... Show more
a manufacturer of proprietary and generic bio preservation media products for cells, tissues and organs
Industry PharmaceuticalsOther
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PTH | 61.54 | 0.94 | +1.56% |
| Invesco Dorsey Wright Healthcare Momentum ETF (PTH) | |||
| TWOX | 30.42 | N/A | +0.01% |
| iShares Large Cap Accelerated Outcome ETF (TWOX) | |||
| DVXB | 20.36 | N/A | N/A |
| Webs Defined Volatility Xlb ETF | |||
| PFOE | 22.16 | -0.02 | -0.11% |
| Pathfinder Focused Opportunities ETF (PFOE) | |||
| EMO | 52.07 | -0.81 | -1.53% |
| ClearBridge Energy Midstream Opportunity Fund | |||
A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with RGEN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then RGEN could also see price increases.
| Ticker / NAME | Correlation To BLFS | 1D Price Change % | ||
|---|---|---|---|---|
| BLFS | 100% | +2.23% | ||
| RGEN - BLFS | 56% Loosely correlated | +3.32% | ||
| RVTY - BLFS | 51% Loosely correlated | +6.03% | ||
| A - BLFS | 50% Loosely correlated | +4.55% | ||
| XRAY - BLFS | 48% Loosely correlated | -2.56% | ||
| DHR - BLFS | 47% Loosely correlated | +1.00% | ||
More | ||||
| Ticker / NAME | Correlation To BLFS | 1D Price Change % |
|---|---|---|
| BLFS | 100% | +2.23% |
| Pharmaceuticals: Other industry (50 stocks) | 46% Loosely correlated | -0.12% |
| Pharmaceuticals industry (154 stocks) | 8% Poorly correlated | +0.61% |
BLFS saw its Momentum Indicator move above the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 108 similar instances where the indicator turned positive. In 89 of the 108 cases, the stock moved higher in the following days. The odds of a move higher are at 82%.
The Moving Average Convergence Divergence (MACD) for BLFS just turned positive on September 22, 2026. Looking at past instances where BLFS's MACD turned positive, the stock continued to rise in 41 of 53 cases over the following month. The odds of a continued upward trend are 77%.
Following a +3.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in 234 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLFS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
BLFS broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BLFS entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. BLFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.396) is normal, around the industry mean (5.014). P/E Ratio (37.740) is within average values for comparable stocks, (162.460). BLFS's Projected Growth (PEG Ratio) (15.094) is slightly higher than the industry average of (4.451). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (16.779) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.